Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Status:
Active, not recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in
patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma,
thymoma (type B2 - B3) and thymic carcinoma, who have progressed after standard therapy.